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Abstract To pro¢le gene expression patterns involved in ische-
mic preconditioning, we monitored global gene expression
changes by DNA microarray analysis of 3200 rat-speci¢c genes
and by real-time quantitative polymerase chain reaction in rat
hearts. Forty-nine genes with altered expression were found
after ischemia/reperfusion as compared to control non-ischemic
hearts and 31 genes were characteristic for classic precondition-
ing followed by ischemia/reperfusion as compared to ischemia/
reperfusion without preconditioning. Genes with altered expres-
sion due to ischemia and/or preconditioning included those con-
trolling protein degradation, stress responses, apoptosis, meta-
bolic enzymes, regulatory proteins, and several unknown cellular
functions. Metallothionein, natriuretic peptides, coagulation fac-
tor VII, cysteine proteinase inhibitor, peroxisome proliferator
activator receptor Q and myosin light chain kinase genes were
previously suspected to be related to several cardiovascular dis-
eases, however, most of these genes have not previously been
shown to be related to myocardial ischemia/reperfusion. Some
genes were observed to change speci¢cally in response to pre-
conditioning: oligoadenylate synthase, chaperonin subunit O, a
cGMP phosphodiesterase (PDE9A1), a secretory carrier mem-
brane protein, an amino acid transporter, and protease 28 sub-
unit. None of these genes has previously been shown to be in-
volved in the mechanism of preconditioning.
4 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Ischemic heart disease is a major cause of mortality in the
western world. E¡ective therapeutic strategies for protecting
the ischemic myocardium are much sought after. Ischemic
preconditioning is a well-described adaptive response in which
brief exposure to ischemia markedly enhances the ability of
the heart to withstand a subsequent ischemic injury (see [1] for
review). Preconditioning confers a remarkable cardioprotec-
tion in a variety of species including humans (see [1,2] for
reviews), although the cardioprotective e¡ectiveness of ische-
mic preconditioning might be attenuated in the heart during
aging and some disease states such as hyperlipidemia and
diabetes (see [3] for review). Preconditioning can be elicited
by di¡erent sublethal stress signals, such as brief periods of
ischemia, hypoxia, rapid electrical pacing, heat stress, admin-
istration of bacterial endotoxin, etc. The cardioprotective ef-
fect of preconditioning shows two distinct phases. The early
phase (classic preconditioning) is manifested within minutes
after the preconditioning stimulus and has a duration of less
than 2^3 h. The late phase is characterized by a slower onset
(20 h) and a duration of up to 72 h.
The underlying molecular mechanisms of ischemic precon-
ditioning have been extensively investigated in the hope of
identifying new rational approaches to therapeutic protection
of the ischemic myocardium. In spite of the intensive research
in the past nearly 2 decades, the exact biochemical mechanism
of preconditioning is still a question of debate due to the
complexity of the cellular mechanisms involved in this phe-
nomenon. A variety of substances and ion channels, i.e. ad-
enosine, bradykinin, nitric oxide, superoxide, peroxynitrite,
calcitonin gene-related peptide, cGMP, protein kinases, nor-
epinephrine, ATP-sensitive Kþ channels, etc., have been
shown so far to play a role both in ischemia/reperfusion injury
and in the development of the cardioprotective e¡ect of pre-
conditioning [2,4,5]. However, the traditional biochemical and
pharmacological approaches have been insu⁄cient so far to
explore the key cellular events in ischemia/reperfusion injury
and preconditioning. Recent studies therefore attempted to
identify gene activity changes during coronary occlusion in
the mouse heart using a mouse cDNA array of 588 genes
[6] and in a rat infarction model using cDNA array of about
7000 rat genes [7]. However, still very little is known about the
gene expression pattern of the heart in response to ischemia/
reperfusion and preconditioning.
Therefore, to pro¢le gene expression patterns associated
with ischemia/reperfusion and classic preconditioning, we
used cDNA microarrays of 3200 rat genes to monitor tran-
script levels in rat hearts in the hope of identifying new cel-
lular pathways involved in cardiac ischemia and ischemic
adaptation.
2. Materials and methods
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
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Health (NIH publication No. 85-23, revised 1996) and was approved
by local ethics committees.
2.1. Perfusion protocol of isolated rat hearts
Male Wistar rats (300^350 g) were anesthetized with diethylether
and given 500 U/kg heparin. Hearts were then isolated and perfused
in Langendor¡ mode with an oxygenated, normothermic Krebs^Hen-
seleit bu¡er as described [8]. Three di¡erent perfusion protocols were
applied (n=5^8 in each group). Hearts were subjected to either a
preconditioning or a non-preconditioning protocol followed by test
ischemia/reperfusion as described in detail [8,9]. After 10 min equili-
bration, preconditioning was induced by three intermittent cycles of
5 min no-£ow ischemia, separated by 5 min aerobic perfusion. Time-
matched non-preconditioned and preconditioned hearts were then
subjected to 30 min global no-£ow ischemia followed by 120 min
reperfusion. A time-matched control group was aerobically perfused
for 190 min. Heart rate and coronary £ow were monitored through-
out the perfusion protocol in all groups [8]. Lactate dehydrogenase
release was measured from coronary e¥uent collected for 5 min at the
beginning of the perfusion and at 0^5 min and 115^120 min of re-
perfusion after 30 min global ischemia and at corresponding periods
in controls as described [8]. At the end of the perfusion protocols,
hearts from all groups were frozen and powdered with a pestle and
mortar in liquid nitrogen.
2.2. RNA preparation
Total RNA was puri¢ed from each group (25^25 mg tissue from
each heart) with NucleoSpin RNA puri¢cation kit (Macherey-Nagel,
Du«ren, Germany) according to the manufacturer’s instructions. RNA
preparations from each group (n=3, randomly selected from each
group) were pooled, and their quantities and qualities were assessed
by gel electrophoresis and spectrophotometry. Total RNA was used
for microarray analysis as well as for reverse transcription quantita-
tive polymerase chain reaction (QRT-PCR).
2.3. Microarrays, probe preparations and hybridizations
Construction and use of microarrays were as described [10]. Brie£y,
3200 ampli¢ed cDNA inserts from rat heart, kidney, liver and brain
libraries were puri¢ed with MultiScreen-PCR plate (Millipore), resus-
pended in 50% dimethyl sulfoxide/water, and arrayed on amino-silan-
ized slides (Sigma-Aldrich, St. Louis, MO, USA) using a MicroGrid
Total Array System (BioRobotics, Cambridge, UK) spotter with 16
pins with a 4U4 format. All clones were spotted in duplicate. After
printing, DNA was UV crosslinked to the slides (Stratagene, Strata-
linker, 700 mJ) and stored at room temperature. Prior to hybridiza-
tion, the slides were blocked in 1Usaline sodium citrate (SSC), 0.2%
sodium dodecyl sulfate (SDS), 1% bovine serum albumin for 30 min
at 42‡C, washed with water and dried with high pressure air. 15 Wg
total RNA from each sample was ampli¢ed by a linear antisense RNA
ampli¢cation method, and labeled with Cy3 or Cy5 £uorescent dye
during reverse transcription as described previously [11]. Brie£y, 2 Wg
of ampli¢ed RNA was labeled with 0.4 WM random nonamers, 0.1
mM d(G/T/A)TPs, 0.05 mM dCTP (Amersham Pharmacia Biotech,
UK), 20 U RNasin (Fermentas, Vilnius, Lithuania), 1U¢rst strand
bu¡er, 200 U RNase H (3) point mutant M-MLV reverse transcrip-
tase (Fermentas), and 0.05 mM Cy3-dCTP or Cy5-dCTP (NEN Life
Science Products, Boston, MA, USA) in 20 Wl total volume. The
RNA, primer and RNasin were denatured at 75‡C for 5 min and
cooled on ice before adding the remaining reaction components. After
2 h incubation at 37‡C, the heteroduplexes were puri¢ed as described
for recovery [12], denatured and the mRNA was alkali hydrolyzed for
15 min at 37‡C and neutralized with 3 M NaOAc (pH 5.0). The
labeled cDNA was puri¢ed with a PCR puri¢cation kit (Macherey-
Nagel) according to the manufacturer’s instructions. Probes generated
from the control and ischemic or preconditioned heart samples were
mixed, reconstituted in 12 Wl hybridization bu¡er (50% formamide,
5USSC, 0.1% SDS, 100 Wg/ml salmon sperm DNA) and applied onto
the array after denaturation by heating for 1 min at 90‡C. The slide
was covered with a 22 mmU22 mm coverslip, and sealed with DPX
Mountant (Fluka, Buchs, Switzerland) in order to prevent evapora-
tion. Slides were incubated at 42‡C for 20 h in a humid hybridization
chamber. After hybridization the mountant was removed and the
arrays were washed by submersion and agitation for 10 min in
1USSC with 0.1% SDS, for 10 min in 0.1%USSC with 0.1% SDS
and for 10 min in 0.1USSC at room temperature, then rinsed brie£y
in deionized water and dried.
2.4. Scanning and data analysis
Each array was scanned under a green laser (532 nm) (for Cy3
labeling) and under a red laser (660 nm) (for Cy5 labeling) using a
ScanArray Lite (GSI Lumonics, Billerica, MA, USA) scanning con-
focal £uorescent scanner with 10 Wm resolution. Image analysis was
performed by ScanAlyze2 software (http://www.microarrays.org/soft-
ware.html). Each spot was de¢ned by manual positioning of a grid of
circles over the image. The average pixel intensity and the local back-
ground of each spot were determined. A measure, i.e. ‘expression
ratio’ (MRAT, denotes the median of the set of background-corrected
single pixel intensity ratios of the two channels within the spot), was
determined [13]. This average expression ratio for all genes on the
array was normalized to 1.0. For background corrections those data
were calculated as negatives where the average intensity of the spot
was smaller than two times the average background of the same area.
Signi¢cant spots have more than 0.55 CHGTB2 values in both Cy3
and Cy5 channels. Each experiment was performed twice using both
£uorescent dyes for labeling control and sample to reduce the number
of false positive or false negative ratios deriving from possible uneven
incorporation of £uorescent dyes during labeling, or from other ex-
perimental variables introduced by hybridization, washing conditions
or array features. Therefore, from each RNA pool two probes were
generated: a Cy5-labeled and a Cy3-labeled one in order to perform
replicate ‘color-£ip’ experiments suggested by other authors [14,15].
Replica spots (on the same array) and replica experiments (two di¡er-
ent arrays) resulted in four data points for every gene. Those spots
were excluded from further analysis when ratios of the replica spots
had a more than two-fold di¡erence. The same restriction was applied
for the average ratios of the replica experiments.
2.5. Real-time quantitative PCR
Relative QRT-PCR was performed on a RotorGene 2000 instru-
ment (Corbett Research, Sydney, Australia) with gene-speci¢c primers
and SybrGreen protocol to con¢rm the gene expression changes
observed by using microarrays. 20 Wg of total RNA from each pool
was reverse transcribed in the presence of poly(dT) sequences in a
total volume of 20 Wl. After dilution of the mix with 80 Wl of water,
2 Wl of this mix was used as template in the QRT-PCR. Relative
expression ratios were normalized to L actin. The PCR primers used
in this study are listed in Table 1. All the PCRs were performed in
triplicate.
Table 1
Primers used in Q-PCR analysis
Gene product Forward primer Reverse primer
L-Actin TTCAACACCCCAGCCATGT GCATACAGGGACAACACAGCC
Chaperonin O TACAGCTCTGCAGATGAAGGATGCTT TGACATCCGTAAGCCTGGAGAATCTG
Natriuretic peptide type B GGACCAAGGCCCTACAAAAGAACTTC GCCGGAGTCTGCAGCCAGGAGGTC
Anion exchange protein 2 CCATGGGTGGCATCTGTGCCCTC GCAGTAGGTCCCCAATGACCATGGAG
Metallothionein-II TCGCCATGGACCCCAACTGCTCCTGTG GAAGCCTCTTTGCAGATGCAGCCCTG
PPARQ CGGAAGCCCTTTGGTGACTTTATGG GATGGGCTTCACGTTCAGCAAGCC
Betaine-homocysteine methyltransferase GGAACCCAGAGTTGCCACCAGATGG AAATCCCCTTTCTGGGGCGAGCTCC
Cysteine proteinase inhibitor GCCACTGCTTGAAAAGAAAACCAATGGG GGTCAGCTCATCATTTTTGGATTTGTTAG
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3. Results and discussion
3.1. Gene expression alteration after ischemia/reperfusion
Relative gene expression changes in response to ischemia
and reperfusion were determined using the expression pro¢les
of time-matched control hearts as baseline. Changes of 3200
genes were followed by rat-speci¢c cDNA microarrays. In
response to ischemia and reperfusion, out of 3200 genes
1468 showed signi¢cant intensity (see Section 2 for statistical
calculations) and 1.6% showed altered expression: 28 genes
exhibited signi¢cant up-regulation and 21 were down-regu-
lated (Table 2). Little is known about the possible role of
most of these genes in ischemia/reperfusion.
In a recent report, global expression analysis in response to
renal ischemia was performed by Yoshida et al. [16]. They
found that most of the genes showing altered expression are
involved in cell structure, extracellular matrix, tissue repair,
and cell division/di¡erentiation. By using an A¡ymetrix oligo-
nucleotide microarray containing 10 000 gene-speci¢c samples
they found 122 genes, the expression of which changed due to
ischemia-induced acute renal failure. In our present study,
several genes with similar characteristics were altered due to
myocardial ischemia, i.e. tubulin, procollagen, glycine-N-acyl-
transferase, several metabolic enzymes and proteins involved
in programmed cell death. We detected extensive changes in
heat shock proteins in our present study. A chaperonin and
two heat shock proteins (86 and 105 kDa) were induced by
ischemia. The induction of heat stress proteins is well known
in response to myocardial, renal, and cerebral ischemia [17^
20], however, this is the ¢rst demonstration that chaperonin
subunit O is signi¢cantly up-regulated due to cardiac ischemia/
reperfusion.
Ischemia/reperfusion repressed several genes including some
mitochondrial genes and aconitase, a major enzyme of the
Table 2
Genes with altered expression in response to ischemia/reperfusion when compared to non-ischemic hearts
Functional cluster Gene product Accession number Ratio S.D.
Bioactive peptides Atrial natriuretic factor M27498 2.68 0.45
Cytoskeleton, extracellular matrix proteins Procollagen, type III, K1 W89883 2.64 0.38
K-Tubulin NM_022298 2.66 0.98
Energy metabolism Mus domesticus strain MilP mitochondrion genome AW545415 0.52 0.1
NADH-ubiquinone oxidoreductase B15 NM_012985 2.28 0.02
Heat shock proteins Chaperonin subunit O AA956164 1.87 0.11
Wagneri gene for 105-kDa heat shock protein AW544862 2.47 0.24
Heat shock protein, 86 kDa 1 AJ428213 3.5 0.5
Metabolic enzymes Glycine-N-acyltransferase AA237628 0.57 0.03
Isocitrate dehydrogenase 3 (NADþ) K NM_053638 1.87 0.38
Formiminotransferase cyclodeaminase NM_053567 0.5 0.05
Aconitase 1 AA875134 0.58 0.1
Others Putative sialoglycoprotease type 2 AA273893 0.56 0.06
Mouse mRNA for AF1q AB083464 0.6 0.01
Elongation factor Tu AA819168 0.6 0.05
14-3-3 protein Q subtype D17447 1.94 0.06
Homo sapiens SPG protein AA067045 2.12 0.07
Mus musculus antigen 4F2 AW545809 2.31 0.07
Mouse histocompatibility 2, class II antigen A K NM_010378 0.58 0.02
GS4 AF492385 1.91 0.03
Homo sapiens CHMP1.5 protein (CHMP1.5) AA066250 2.46 0.16
Signal peptidase NM_031723 2.8 0.34
Homo sapiens HSPC245 AA260293 2.01 0.15
Glutaminyl-tRNA synthetase BE329136 1.99 0.26
Receptors, ion channels, membrane proteins Cytokine receptor-like molecule AA899612 0.59 0.06
Low-density lipoprotein receptor-related protein NM_053541 0.6 0.01
Homo sapiens solute carrier family 39 (zinc transporter) NM_130849 0.45 0.04
Regulatory proteins, kinases, phosphatases Homo sapiens zinc ¢nger protein 28 AW536277 2.03 0.18
Fas-activated serine/threonine FAST kinase AA956496 1.93 0.19
Mus musculus forkhead protein FKHR AA221124 2.11 0.21
Signal transduction Ras oncogene neuroblastoma, Nras NM_080766 0.59 0.12
Synaptic proteins Synaptic vesicle protein 2B AF372834 0.44 0.16
Ubiquitin system Non-canonical ubiquitin conjugating enzyme 1 AA250689 0.6 0.01
Rattus norvegicus ubiquitin-like protein AW545652 2.45 0.39
Unknown EST AA276424 0.55 0.11
Human DNA sequence from clone 1178H5 AW541466 0.58 0.04
Homo sapiens 12q15 BAC RPCI11-444B24 AW545696 0.58 0.14
EST AA261708 0.59 0.04
EST AA268104 0.59 0.01
Clone: 4933424L15: L-defensin-containing protein NM_031810 0.6 0.06
EST AA388512 1.99 0.14
Mus musculus clone: 2510040L10 AA244814 2.04 0.21
EST AA242702 2.07 0.17
Homo sapiens unknown protein IT12 AW536219 2.18
EST AA412944 2.32 0.14
EST AA073606 2.37 0.24
EST AA266972 2.49 0.49
Drosophila melanogaster genomic sequence AA407331 2.91 0.98
All experiments were done in duplicate and data were calculated from four intensity ratios. ‘EST’ denotes expressed sequence tag.
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citrate cycle. It is well known that ischemia/reperfusion results
in mitochondrial damage leading to cell apoptosis or necrosis
[21^23], however, little is known about the cellular mecha-
nisms of these phenomena.
Lynn et al. studied the gene expression pro¢le of ischemic
injury produced by left coronary artery occlusion without
reperfusion in mouse hearts. They used an array with only
588 gene-speci¢c probes and found only a small number of
genes a¡ected by ischemia. Genes with altered expression were
those encoding proteins implicated in oxidative stress, apopto-
sis and cardiac muscle development [6]. In a rat infarction
model, a detailed gene expression analysis was performed us-
ing a microarray containing 7000 cDNAs [7] and several genes
encoding proteins involved in cytoskeletal architecture, con-
tractility, and metabolism were identi¢ed. In accordance with
their ¢ndings, we found several genes in the present study
which exhibited changes in expression in response to ische-
mia/reperfusion, i.e. heat shock proteins, ubiquinone oxidore-
ductase, ubiquinone binding protein, collagen, tubulin, and
atrial natriuretic factor.
In our present study, several clones encoding hypothetical
proteins or ESTs having no homology to known proteins
exhibited signi¢cant up- or down-regulation. The cellular
function of these genes and their relationship to myocardial
ischemia/reperfusion needs to be elucidated.
3.2. Gene expression alteration due to preconditioning
To study the e¡ects of preceding preconditioning on ische-
mia/reperfusion-induced gene expression patterns, we used
cDNA microarrays to monitor alterations in gene expression
of ischemic rat hearts with and without preconditioning.
Genes exhibiting characteristic changes in expression due to
preconditioning are shown in Table 3. Out of 3200 rat genes
1450 had signi¢cant intensity values but only 1% of them
showed altered expression: 14 clones were overexpressed
and 17 repressed (see Section 2 for statistical calculations).
In order to con¢rm the di¡erential expression of genes re-
vealed by microarray analysis of rat hearts after ischemia with
and without preconditioning, several genes were analyzed by
real-time £uorescent QRT-PCR. We selected seven genes of
which the expression was signi¢cantly altered in precondi-
tioned hearts for real-time RT-PCR analysis (Fig. 1). The
di¡erential expression of these genes revealed an almost per-
fect concordance with the microarray data. Genes encoding
chaperonin subunit O, anion exchange protein 2 and metal-
lothionein II had a very signi¢cant rise in transcription rate,
Table 3
Genes with altered expression due to preconditioning followed by ischemia/reperfusion when compared to either ischemic/reperfused hearts
without preconditioning or non-ischemic controls
Functional cluster Gene product Accession
number
Ratio 1
(Isc/Norm)
S.D.
(1)
Ratio 2
(Prec/Isc)
S.D.
(2)
Bioactive peptides Natriuretic peptide precursor type B NM_031545 0.73 0.06 1.76 0.21
Calcium-dependent binding
proteins
Pentaxin-related gene W42321 0.97 0.09 1.80 0.24
Cytoskeleton, extracellular
matrix proteins
Class I L-tubulin AB011679 0.65 0.18 0.66 0.01
Heat shock proteins Chaperonin subunit 5, O AA955792 1.87 0.11 2.18 0.21
Metabolic enzymes (2P,5P)Oligoadenylate synthase 1 Z18877 1.17 0.15 1.75 0.14
cGMP phosphodiesterase (PDE9A1) AA273765 1.51 0.26 3.29 0.89
Peroxisome proliferator activator receptor Q NM_013124 0.95 0.23 0.50 0.14
Protease (macropain) 28 subunit, K NM_017278 1.1 0.31 0.56 0.13
Betaine-homocysteine methyltransferase NM_030850 1.36 0.21 0.57 0.05
N-Acylsphingosine amidohydrolase 1 NM_053407 1.21 0.19 1.70 0.22
Metal binding proteins Metallothionein II H32024 1.08 0.16 1.69 0.08
Others 18S, 5.8S, and 28S ribosomal RNAs V01270 2.8 0.29 1.85 0.14
Coagulation factor VII AA271041 1.29 0.2 1.99 0.21
Nucleolar phosphoprotein of 140 kDa AA408077 1.07 0.19 2.03 0.31
Heparin cofactor II AF096869 1.08 0.09 2.08 0.42
L-Globin X05080 1.08 0.34 0.66 0.01
Kell blood group glycoprotein AA900226 0.86 0.11 0.51 0.18
Cysteine proteinase inhibitor M92418 0.98 0.09 0.63 0.11
Receptors, ion channels,
membrane proteins
Secretory carrier membrane protein (SCAMP3) AF005036 1.78 0.27 1.59 0.05
Neutral and basic amino acid transporter U10110 1.78 0.38 1.64 0.14
Anion exchanger 2 NM_017048 1.76 0.29 1.84 0.28
Lymphatic endothelium-speci¢c hyaluronan
receptor Lyve-1
AA269330 1.88 0.11 0.58 0.01
Regulatory proteins, kinases,
phosphatases
Myosin light chain kinase AW142114 1.02 0.24 0.59 0.14
Signal transduction Frizzled homolog 4 AW140615 1.2 0.09 0.55 0.19
Unknown Unknown protein AA259369 1.09 0.08 3.11 0.64
Unknown protein W34106 1.42 0.18 0.47 0.02
Unknown protein AA260880 0.92 0.25 0.54 0.21
Unknown protein AW539764 1.03 0.06 0.55 0.08
Unknown protein AA259659 1.42 0.25 0.57 0.04
Unknown protein AA277040 0.78 0.13 0.59 0.14
Unknown protein 1.27 0.11 0.62 0.09
All experiments were done in duplicate and data were calculated from four intensity ratios. ‘Isc’ denotes ischemia/reperfusion, ‘Norm’ non-is-
chemic controls, and ‘Prec’ preconditioning.
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while the natriuretic peptide precursor type B gene showed a
less pronounced induction. Genes encoding peroxisome pro-
liferator activator receptor Q (PPARQ) and betaine-homocys-
teine methyltransferase showed repression, although the cys-
teine proteinase inhibitor gene exhibited moderate repression
at the mRNA level.
Changes in the expression of some genes by preconditioning
followed by ischemia/reperfusion were similar to those
changed by ischemia/reperfusion alone (overexpressed: a se-
cretory membrane protein, an amino acid transporter, an
anion exchanger, a ribosomal RNA and a chaperonin gene;
repressed: L-tubulin). Because in the case of preconditioning
the control sample was ischemia/reperfusion alone, the expres-
sion of these genes changed more dramatically when com-
pared to non-ischemic controls. This suggests that these genes
might have signi¢cant roles in ischemic adaptation of the
heart during single ischemia without preconditioning as well.
The rest of the genes listed in Table 3 are those which were
speci¢cally and di¡erentially expressed in response to precon-
ditioning and were not altered after single ischemia/reperfu-
sion. Among these genes metallothionein, coagulation factor
VII, cysteine proteinase inhibitor, PPARQ and myosin light
chain kinase genes were previously shown to have connections
with ischemia or other heart diseases [24^33]. Hypoxia pre-
conditioning induced the expression of metallothionein in the
brain [25]. We found here that the (2P,5P)oligoadenylate syn-
thase gene showed overexpression in response to precondi-
tioning. It has been previously shown by others that the
mRNA level of this gene rose more than two- to three-fold
after 24 h recovery from ischemia in the rat brain [26]. There-
fore, it is plausible to speculate that oligoadenylate synthase
might have a protective e¡ect on the heart as well. Chaper-
onin subunit O and natriuretic peptide precursor type B also
exhibited up-regulation due to preconditioning. None of these
genes has previously been shown to be involved in precondi-
tioning.
A more dramatic induction was detected in the expression
of a cGMP phosphodiesterase (PDE9A1). Alterations in
cGMP levels in the heart have previously been shown in re-
sponse to preconditioning [27], however, this is the ¢rst dem-
onstration that the expression of a phosphodiesterase gene is
altered due to preconditioning.
PPARQ exhibited one of the most pronounced repressions
due to preconditioning. PPARQ has been shown to be in-
volved in several cardiovascular pathologies including athero-
sclerosis and ischemic heart disease, however, this is the ¢rst
demonstration that PPARQ plays a role in ischemic precondi-
tioning. Interestingly, most of the previous studies show that
pharmacological activation of PPARQ protects the ischemic
heart [28^30]. In contrast, our present study shows that pre-
conditioning leads to a marked repression of the PPARQ gene.
This suggests that the role of PPARQ in ischemic injury and
ischemic adaptation is still unclear.
Degradation of myocardial structural proteins in myocar-
dial infarction has been shown to be reduced by a cysteine
proteinase inhibitor [31]. In our present study a 1.59-fold re-
pression was detected by microarray analysis and a 1.75-fold
repression by real-time quantitative PCR. It seems that the
activity of cysteine proteases is favored in preconditioning.
Another gene related to protein degradation was also re-
pressed: protease 28 subunit had a 1.79-fold repression; this
gene has a regulatory function in proteasome for small protein
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Fig. 1. Quantitative determination of transcript levels by real-time
PCR. Changes in transcript levels in rat hearts during ischemia
(light box) and ischemia with preconditioning (dark box) were con-
¢rmed by triplicate real-time PCR. L-Actin was used as a control.
The expression of the following genes was determined: chaperonin
subunit O : che ; natriuretic peptide precursor type B: npp ; anion ex-
change protein 2: aex ; metallothionein II: mth ; peroxisome prolifer-
ator activator receptor Q : pparg ; betaine-homocysteine methyltrans-
ferase: bmh ; cysteine proteinase inhibitor: cpi. Dashed lines indicate
the interval 31.8- to 1.8-fold regulation (corresponding to
log10 = 0.255) in which changes in expression were considered not
signi¢cant.
Table 4
Heart rate, coronary £ow, and lactate dehydrogenase (LDH) release in non-ischemic time-matched control, ischemia/reperfusion, and precondi-
tioning+ischemia/reperfusion groups at the beginning of perfusion, upon early reperfusion (rep.) and at the end of the reperfusion in isolated
rat hearts
Group Basal 5 min rep. 120 min rep.
Heart rate (beats/min)
Non-ischemic control 244^ 4 243^ 5 244^ 5
Ischemia/reperfusion 240^ 4 246^ 12 249^ 9
Preconditioning+ischemia/reperfusion 248^ 6 248^ 12 246^ 7
Coronary £ow (ml/min/g)
Non-ischemic control 14.7^ 1.0 17.0^ 1.0 17.0^ 0.9
Ischemia/reperfusion 15.8^ 1.1 15.7^ 2.9 12.2^ 1.2*
Preconditioning+ischemia/reperfusion 15.6^ 1.2 16.3^ 1.6 15.6^ 0.9
LDH release (mU/min/g)
Non-ischemic control nd nd nd
Ischemia/reperfusion nd 671^ 98* 422^ 72*
Preconditioning+ischemia/reperfusion nd 148^ 56*# 223^ 57*
Data are means^S.E.M.; nd, non-detectable, below the detection limit (n=5^8 in each group).
*P6 0.05 vs. corresponding control, #P6 0.05 vs. ischemia/reperfusion.
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substrate degradation [32] and has implications for oxidative
stress [33].
3.3. Limitations of the study
The stability of the preparation upon long-term perfusion is
a general concern in isolated heart preparations. Here we used
a Langendor¡ preparation with no left ventricular balloon to
unload the heart from ‘afterload pressure’ and to maintain a
good coronary perfusion throughout the perfusion protocol.
As shown in Table 4, in the non-ischemic time-matched con-
trol group, heart rate and coronary £ow were stable and no
LDH release was detected which show the stable aerobic con-
dition of the heart. Preconditioning signi¢cantly decreased
postischemic LDH release showing the well-known cardiopro-
tective e¡ect of preconditioning in this model (Table 4). As
the present study was performed in crystalloid-perfused iso-
lated rat hearts and the analysis of gene expression was done
using cardiac tissue that did not contain components of blood,
the mechanisms of ischemia/reperfusion injury and precondi-
tioning might be somewhat di¡erent in the present ex vivo
experimental model as compared to in vivo situations. A fur-
ther limitation of the present study is that analysis of cardiac
tissue for gene expression pattern was done at the end of the
2-h reperfusion to allow time for mRNA accumulation and/or
degradation. Therefore, the present study cannot distinguish
between the ‘trigger’ and ‘mediator’ genes of preconditioning
(see [2^4] for reviews); however, addressing this issue raises
many technical problems in study design and needs further
studies in the future.
In summary, here we present a number of genes of which
the expression is signi¢cantly altered due to ischemia/reperfu-
sion and preconditioning in the heart. Although some of the
genes have previously been shown to play a role in ischemia/
reperfusion injury, this is the ¢rst demonstration that most of
the genes presented here are involved in classic precondition-
ing and ischemia/reperfusion. The newly identi¢ed genes in
our present study might lead to a better understanding of
the cellular mechanisms of the remarkable cardioprotection
elicited by ischemic preconditioning.
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